[This article was first published in Army Sustainment Professional Bulletin, which was then called Army Logistician, volume 2, number 5 (September–October 1970), pages 12–13. The text is ...

InflaRx (NASDAQ:IFRX – Get Free Report) is expected to issue its quarterly earnings data before the market opens on Thursday, March 20th. Analysts expect the company to announce earnings of ($0.27) ...

Multiple analyses also showed vilobelimab can promote significant and sustained reductions in C5a, which is a key mediator of the inflammatory cascade. We believe that the C5a/C5aR pathway remains ...

Patrycja Humienik’s debut poetry collection, “We Contain Landscapes,” explores chronic illness, climate change, borders and ...

N.V. announced the presentation of multiple posters describing the utility of vilobelimab in pyoderma gangrenosum and ...

The FDA first approved eculizumab for use in adult patients with generalized myasthenia gravis in 2017, before expanding the ...

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.

Vilobelimab is a first-in-class monoclonal anti-human complement factor C5a antibody, which targets the biological activity of C5a and demonstrates high selectivity towards its target in human blood.

Results C5a generated after the injection of MSU primed the inflammasome for IL-1β release. Neutrophils infiltrating the peritoneum in response to C5a released phosphatidylserine (PS)-positive ...